ProCE Banner Activity

Optimizing Immunotherapy for Advanced Non-Small-Cell Lung Cancer in Today’s Patients

Clinical Thought

Experts discuss key points for optimizing the use of immune checkpoint inhibitor therapies, including individualizing therapy decisions and managing adverse events, in patients with advanced NSCLC.

Released: May 31, 2022

Expiration: May 30, 2023



Julia Rotow

Julia Rotow, MD

Medical Oncologist
Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts


This activity is supported by educational grants from Bristol Myers Squibb; Genentech, a member of the Roche Group; Merck Sharp & Dohme Corp.; and Regeneron Pharmaceuticals, Inc and Sanofi.


Bristol Myers Squibb

Genentech, a member of the Roche Group

Regeneron Pharmaceuticals, Inc


Target Audience

NPs and PAs in oncology


Julia Rotow, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Chia Tai Tianqing, Eli Lilly, Gritstone Bio, Janssen, Jazz, Merck, Pfizer, Sanofi-Genzyme

None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.


Clinical Thought


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Additional Information

Program Medium

This program has been made available online.